Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ROBO1 Specific BiCAR-NK/Tcell therapy

Next Previous
Drug Profile

ROBO1 Specific BiCAR-NK/Tcell therapy

Alternative Names: BiCAR-NK/T cells - Asclepius Technology Company Group; ROBO1 CAR-NK/T cell immunotherapy - Asclepius Technology Company Group

Latest Information Update: 14 May 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asclepius Technology Company Group
  • Class CAR-NK cell therapies; CAR-T cell therapies; Gene therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 May 2019 Phase-I/II clinical trials in Solid tumours (In adults, In the elderly, Late-stage disease) in China (Parenteral) (NCT03940820)
  • 01 May 2019 Phase-I/II clinical trials in Pancreatic cancer (Metastatic disease) in China (Parenteral) (NCT03941457)
  • 01 May 2019 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, In adults, In the elderly) in China (Parenteral) before May 2019 (NCT03931720)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top